Jesús ArenasEditorial on the Research Topic
Pathogenic Neisseria: Pathogenicity, vaccines, and antibiotic resistance
The genus Neisseria includes commensal species that form part of the flora of human and animal mucosa, but also includes two major pathogenic species: Neisseria gonorrhoeae and Neisseria meningitidis. N. meningitidis inhabits the upper respiratory tract and can cause meningococcal disease, a disease of rapid onset that involves sepsis and meningitis. N. gonorrhoeae lives in the genital, rectal and oral mucosa, and can cause gonorrheal infection that involves pelvic inflammatory disease, infertility, ectopic pregnancy, and neonatal blindness when transferred from an infected mother to the neonate during delivery. Recent discoveries expand our knowledge about interbacterial interactions, vaccine development and diagnostics.
Both Neisseria species are exclusively adapted to humans, therefore they evolved mechanisms to persist human defenses, acquire nutrients from the host and compete with the bacterial microbiome. Indeed, in vivo studies gained evidences that different Neisseria species can colonize a host at multiple sites of the nasopharynx and oral cavity (Sáez Nieto et al., 1998; Donati et al., 2016), and that N. lactamica prevented N. meningitidis colonization (Evans et al., 2011; Deasy et al., 2015), suggesting inter species competition. In the report by Baerentsen et al. competition mechanisms amongst Neisseria sp are summarized, comprising polymorphic toxins, bacteriocins and methylated DNA. Polymorphic toxins were discovered last decade and involve the Two Partner Secretion System (Arenas et al., 2013) and the MafA/B system (Arenas et al., 2015; Jamet et al., 2015). Both systems follow a similar genetic organization. However, TpsA and MafB toxins are structurally different, including secretion systems, toxin delivery, toxin processing, and protein production. Therefore its biological functions can substantially differ. But Neisseria can potentially produce bacteriocins or toxic metabolites, for example gonocins (Flynn and McEntergart, 1972) or meningocins (Kingsbury, 1966), which can also inhibit the growth of gonococcus or several Neisseria, respectively. The origin of these substances remains unclear but could help to discover antibiotic alternatives. A new and fascinating system is DNA methylation, which has been demonstrated to take place between N. elongata and N. gonorrhoeae or N. meningitidis (Kim et al., 2019). In the proposed model, DNA is transferred between bacteria, and the high degree of sequence homology allows multiple recombination. At these sites, methylation mismatch leading to restriction enzyme cleavage and chromosome degradation (Kim et al., 2019; So and Rendon, 2019).
Capsular and subcapsular commercial vaccines against N. meningitidis have been developed so far, and they cover the most relevant disease related serogroups (Pizza et al., 2020). However, commercial vaccines against N. gonorrhoeae are lacking, while the number of antimicrobial resistant clinical isolates is drastically increasing worldwide. High frequency phase and antigenic variation of surface exposed antigens appears to be one of the main drawbacks to promote vaccine development. This is illustrated in the work conducted by Shaskolskiy et al., who reported a comparative whole-genome analysis for N. gonorrhoeae isolates of genogroup 807, the most common in the Russian Federation, to other predominant genogroups worldwide. Authors found about 8-20 specific genes to each sequence type, including loci for phase variation and components of the gonococcal genetic island. Also, gene substitutions, mutations and absence in T4SS DNA secretion system encoding genes were detected. Remarkably, a variety of alleles of genes coding for pili proteins, transmembrane transporters, or components of MafA/B systems, amongst many others, were identified. Overall, clinical N. gonorrhoeae isolates expose a variety of structures at the surface, which makes difficult to find antigens to unsure cross protection in a universal vaccine. Maurakis and Cornelissen revised the most recent studied antigens, including TonB dependent transporters, lipo-oligosaccharides epitopes, and OMVs based or bacterial ghost vaccines. The transferrin binding protein A and B were largely studied, also in N. meningitidis, because of conservation, surface exposition and immunogenicity. But membrane proteins undergo problems for antigen production and stabilization. To overcome these issues, successful hybrids fusing TbpA loop 2 to the N-terminal lobe of TbpB were generated and elicited protective antibodies (Price et al., 2007). Besides, some LOS epitopes, such as L8 or 2C7, which are conserved amongst gonococci, resulted immunogenic, and stimulated bactericidal IgG responses in mice (Gulati et al., 1996; Ram et al., 2018; Gulati et al., 2019). Antigen platforms were also examined, including OMVs based vaccines, which had shown good results in the generation of meningococcal vaccines. Examples include IL-12 encapsulated OMVs (Liu et al., 2018), fHBP overexpression OMVs and an attenuated lipid A OMVs (Beernink et al., 2019) or detoxified meningococcal OMVs (Kathryn et al., 2022). Also, bacterial ghost, which are empty shells, are being used for antigen delivery such as NspA (Jiao et al., 2021).
Rapid and accurate diagnosis is critical for timely treatment of Neisserial infections. In line with this, spherical goal nanoparticles with shorth single DNA strand linked at the particle surface were developed by Carter et al to rapidly identify gonococcal DNA. The probe DNA is complementary to gonococcal DNA uptake sequences, highly abundant in gonococcal genomes. They can hibridate gonococcal DNA and induces particle aggregation that can be colorimetrically detected. Identification of gonococcal DNA in samples from patients could takes about 30 min, and thus can be a fast and routinary technique. But, also, rapid detection of antibiotic resistance is critical for adequate treatment of Neisserial infections. N. gonorrhoeae rapidly develop antimicrobial resistance, including to sulfonamides, penicillins and fluoroquinoles (Lorenzo-Lurenco et al., 2017; Aitolo et al., 2021). Ciprofloxacin is a quinolone used for treatment of meningococcal and gonococcal infection. Ciprofloxacin activity is based on the its interaction with DNA gyrase and topoisomerases. Ciprofloxacin resistance is attributed to mutations in target genes, i.e. gyrA or parC genes that codes for subunits of gyrase and topoisomerase. The gold standard technique to detect the origin of ciprofloxacin resistance is sequencing, but it is time consuming. To overcome this issue, a rapid test combining mismatch PCR targeting gyrA and subsequent digestion patterns of PCR products with AciI was proposed by Ota et al. This method based on the detection of T91I mutation in gyrA, one of the most common mutations that confer ciprofloxacin resistance. Identification of ciprofloxacin can take 4 hours and does not require bacterial growth.
In summary, the work published here reinforces the knowledge about two pathogenic species and the development of novel techniques for diagnosis and prevention. I hope that this Research Topic will stimulate new research in this field where comprehensive molecular mechanisms remain to be elucidated.
Author contributions
JA (University of Zaragoza, Spain) edited this Research topic and wrote the manuscript. The author contributed to the article and approved the submitted version.
Funding
JA received funding from Gobierno de Aragón (Department of Science, University and knowledge Society) (Project TRANSIT, Grant agreement LMP58_21) and from Ministerio de Ciencia e Innovación/Agencia Española de Investigación MCIN/AEI/10.13039/501100011033 (Project ABC-VACCINESs, Grant agreement PID2020-114617RB-100).
Acknowledgments
Nahan Weyand (Ohio University, United States) edited this Research Topic. I thank the authors of the papers published on this Research Topic.
Conflict of interest
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Aitolo, G. L., Adeyemi, O. S., Afolabi, B. L., Owolabi, A. O. (2021). Neisseria gonorrhoeae antimicrobial resistance: past to present to future. Curr. Microbiol. 78, 867–878. doi: 10.1007/s00284-021-02353-8
Arenas, J., de Maat, V., Catón, L., Krekorian, M., Herrero, J. C., Ferrara, F., et al. (2015). Fratricide activity of MafB protein of neisseria meningitidis strain B16B6. BMC Microbiol. 15, 156. doi: 10.1186/s12866-015-0493-6
Arenas, J., Schipper, K., van Ulsen, P., van der Ende, A., Tommassen, J. (2013). Domain exchange at the 3' end of the gene encoding the fratricide meningococcal two-partner secretion protein a. BMC Genomics 14, 622. doi: 10.1186/1471-2164-14-622
Beernink, P. T., Ispasanie, E., Lewis, L. A., Ram, S., Moe, G. R., Granoff, D. M. (2019). Meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and overexpressed factor h binding protein elicits gonococcal bactericidal antibodies. Infect. Dis. 15, 1130–1137. doi: 10.1093/infdis/jiy609
Deasy, A. M., Guccione, E., Dale, A. P., Andrews, N., Evans, C. M., Bennett, J. S., et al. (2015). Nasal inoculation of the commensal neisseria lactamica inhibits carriage of neisseria meningitidis by young adults: A controlled human infection study. Clin. Infect. Dis. 15, 1512–1520. doi: 10.1093/cid/civ098
Donati, C., Zolfo, M., Albanese, D., Truong, D. T., Asnicar, F., Lebba, V., et al. (2016). Uncovering oral neisseria tropism and persistence using metagenomic sequencing. Nat. Microbiol. 27, 16070. doi: 10.1038/nmicrobiol.2016.70
Evans, C. M., Pratt, C. B., Matheson, M., Vaughan, T. E., Findlow, J., Borrow, R., et al. (2011). Nasopharyngeal colonization by neisseria lactamica and induction of protective immunity against neisseria meningitidis. Clin. Infect. Dis. 52, 70–77. doi: 10.1093/cid/ciq065
Flynn, J., McEntegart, M. G. (1972). Bacteriocins from neisseria gonorrhoeae and their possible role in epidemiological studies. J. Clin. Pathol. 25, 60–61. doi: 10.1136/jcp.25.1.60
Gulati, S., McQuillen, D. P., Mandrell, R. E., Jani, D. B., Rice, P. A. (1996). Immunogenicity of neisseria gonorrhoeae lipooligosaccharide epitope 2C7, widely expressed in vivo with no immunochemical similarity to human glycosphingolipids. J. Infect. Dis. 174, 1223–1237. doi: 10.1093/infdis/174.6.1223
Gulati, S., Pennington, M. W., Czerwinski, A., Carter, D., Zheng, B., Nowak, N. A., et al. (2019). Preclinical efficacy of a lipooligosaccharide peptide mimic candidate gonococcal vaccine. mBio 10, e02552–19. doi: 10.1128/mBio.02552-19
Jamet, A., Jousset, A. B., Euphrasie, D., Mukorako, P., Boucharlat, A., Ducousso, A., et al. (2015). A new family of secreted toxins in pathogenic neisseria species. PloS Pathog. 11, e1004592. doi: 10.1371/journal.ppat.1004592
Jiao, H., Yang, H., Zheng, W., Zhang, Q., Zhao, D., Li, G. (2021). Enhancement of immune responses by co-administration of bacterial ghosts-mediated neisseria gonorrhoeae DNA vaccines. J. Appl. Microbiol. 130, 1770–1777. doi: 10.1111/jam.14815
Kathryn, A., Matthias, K. A., Connolly, K. L., Begum, A. A., Jerse, A. E., Macintyre, A. N. (2022). Meningococcal detoxified outer membrane vesicle vaccines enhance gonococcal clearance in a murine infection model. J. Infect. Dis. 225, 650–660. doi: 10.1093/infdis/jiab450
Kim, W. J., Higashi, D., Goytia, M., Rendón, M. A., Pilligua-Lucas, M., Bronnimann, M., et al. (2019). Commensal neisseria kill neisseria gonorrhoeae through a DNA-dependent mechanism. Cell Host Microbe 26, 228–239. doi: 10.1016/j.chom.2019.07.003
Kingsbury, D. T. (1966). Bacteriocin production by strains of neisseria meningitidis. J. Bacteriol. 91, 1696–1699. doi: 10.1128/jb.91.5.1696-1699
Liu, Y., Perez, J., Hammer, L. A., Gallagher, H. C., De Jesus, M., et al. (2018). Intravaginal administration of interleukin 12 during genital gonococcal infection in mice induces immunity to heterologous strains of neisseria gonorrhoeae. mSphere 3, e00421–17. doi: 10.1128/mSphere.00421-17
Lorenzo-Lurenco, A. P. R., dos santos, B. K. T., Moreira, B. M., Fracalanzza, S. E. L., Bonelli, R. R. (2017). ¨Antimicrobial resistance in neisseria gonorrhoeae: History, molecular mechanisms and epidemiological aspects of an emerging global threat”. Braz. J. Microbiol. 48, 617–628.
Pizza, M., Bekkat-Berkani, R., Rappuoli, R. (2020). Vaccines against meningococcal diseases. Microorganisms 8, 1521. doi: 10.3390/microorganisms8101521
Price, G. A., Masri, H. P., Hollander, A. M., Russell, M. W., Cornelissen, C. N. (2007). Gonococcal transferrin binding protein chimeras induce bactericidal and growth inhibitory antibodies in mice. Vaccine 25, 7247–7260. doi: 10.1016/j.vaccine.2007.07.038
Ram, S., Gulati, S., Lewis, L. A., Chakraborti, S., Zheng, B., DeOliveira, R. B., et al. (2018). A novel sialylation site on neisseria gonorrhoeae lipooligosaccharide links heptose II lactose expression with pathogenicity. Infect. Immun. 86, e00285–18. doi: 10.1128/IAI.00285-18
Sáez Nieto, J. A., Marcos, C., Vindel, A. (1998). Multicolonization of human nasopharynx due to neisseria spp. Int. Microbiol. 1, 59–63.
Keywords: Neisseria meningitidis, Neisseria gonorrhoeae, vaccines, antibiotic resistance, bacteria competition, mafA/B system, two partner secretion system
Citation: Arenas J (2023) Editorial: Pathogenic Neisseria: Pathogenicity, vaccines, and antibiotic resistance. Front. Cell. Infect. Microbiol. 12:1119244. doi: 10.3389/fcimb.2022.1119244
Received: 08 December 2022; Accepted: 21 December 2022;
Published: 05 January 2023.
Edited and Reviewed by:
Alain Filloux, Imperial College London, United KingdomCopyright © 2023 Arenas. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jesús Arenas, Jarenasbusto@gmail.com; jaarenas@unizar.es